Misako Nagasaka, MD, PhD

home / authors / misako-nagasaka-md-phd

Associate Clinical Professor, Division of Hematology/Oncology, Medicine
Medical Oncologist
- Lung Cancer
- Thoracic Oncology
Languages
- English
- Japanese

Articles

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

Misako Nagasaka, MD, PhD

December 10th 2024

Dr Nagasaka discusses the use of T-DXd in patients with unresectable or metastatic HER2-positive NSCLC.

Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 Trial

Misako Nagasaka, MD, PhD

July 30th 2024

Misako Nagasaka, MD, PhD, discusses the use of trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer and recent NCCN guideline updates based on the DESTINY-Lung-01 HER2 overexpression cohort data.

Dr Nagasaka on the Efficacy of Repotrectinib in Locally Advanced/Metastatic ROS1+ NSCLC

Misako Nagasaka, MD, PhD

January 11th 2024

Misako Nagasaka, MD, discusses key data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ non–small cell lung cancer.

Closing Expert Perspectives on Treatment in Advanced NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

June 2nd 2022

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.

Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

June 2nd 2022

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Recent Advances in Treatment of ROS1-Rearranged NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 25th 2022

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.

Updates in Treatment of NSCLC with ALK Rearrangements

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 25th 2022

Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.

Treatment Selection and Sequencing for Patients with NTRK Fusions in Clinical Practice

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 17th 2022

A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.

Recent Advances in Treatment of NSCLC with NTRK Fusions

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 11th 2022

Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.

Treatment of KRAS G12C Mutant NSCLC

Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Benjamin Levy, MD;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 11th 2022

Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.

Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 5th 2022

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Updates in Treatment of HER2 Mutant NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 5th 2022

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 2nd 2022

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

Updates in Treatment of NSCLC with Classical EGFR Mutations

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 2nd 2022

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Challenges Associated with Molecular Testing in NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 19th 2022

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 19th 2022

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 12th 2022

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 12th 2022

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.